Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

11.80EUR
26 Jun 2017
Change (% chg)

€0.15 (+1.29%)
Prev Close
€11.65
Open
€11.75
Day's High
€11.87
Day's Low
€11.74
Volume
74,373
Avg. Vol
122,837
52-wk High
€14.69
52-wk Low
€8.21

Select another date:

BRIEF-Ablynx initiates study of caplacizumab in healthy Japanese subjects

* ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS

BRIEF-Ablynx to receive 15 million euros milestone payment

* NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT

BRIEF-Ablynx Q1 revenues eur 9.1 million (2016 eur 27.4 million)

* Q1 OPERATING LOSS OF EUR 20.2 MILLION (2016: LOSS EUR 0.7 MILLION)

BRIEF-Ablynx completes patient recruitment in its Phase III HERCULES study of caplacizumab for the treatment of aTTP

* Ablynx completes patient recruitment in its Phase III HERCULES study of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)

BRIEF-Ablynx announces warrant exercise

* An additional 57,125 common shares have been issued by company in exchange for EUR 398,801.77 ($427,395.86) as result of exercise of warrants

BRIEF-Ablynx FY revenue rises 10 pct

* FY net cash burn of EUR 72.2 million, in line with previously guided range of EUR 65-75 million

BRIEF-Ablynx: Results support advancement of vobarilizumab into phase III development

* Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, a potential best-in-class treatment for rheumatoid arthritis

BRIEF-Ablynx submits marketing authorisation for caplacizumab

* Ablynx submits a marketing authorisation application to the European medicines agency for caplacizumab, its anti-vwf nanobody, for the treatment of aTTP

BRIEF-Ablynx's partner Merck reports encouraging results with nanobody

* Ablynx's partner, Merck KGaA, reports encouraging results with the bi-specific nanobody anti-il-17a/f (m1095) in a phase ib clinical study in patients with psoriasis

BRIEF-Van Herk Investments announces 10.07 pct shareholding in Ablynx

* Van Herk Investments B.V. announces 10.07 pct shareholding in Ablynx, an increase from a former position of 5.40 pct (August 2016) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date:

More From Around the Web